MINNEAPOLIS--(BUSINESS WIRE)--NightWare, the manufacturer of the FDA-cleared digital therapeutic device that treats PTSD-related nightmares, announced today that it has launched an equity crowdfunding campaign on StartEngine.
The NightWare device is a dedicated non-invasive medical device using an AI algorithm that identifies when a nightmare is occurring and nudges the user out of the nightmare without waking them.
“We are very excited about this campaign,” says NightWare CEO Matthew Tucker. “The raise supports our mission to improve sleep health for PTSD sufferers.”
The NightWare device is an FDA Breakthrough Device and was cleared in 2020 by the FDA to treat Nightmare Disorder, a condition related to PTSD that is formally recognized in the DSM 5. The non-invasive, non-pharmaceutical NightWare device has helped over 1,500 sufferers to-date.
“While we are gratified that we have been able to help so many patients, we know that 80% of PTSD patients experience disturbing nightmares and that Nightmare Disorder is related to an increased risk of suicide,” explains Tucker. “This capital raise will help us expand access and provide relief to these sufferers with a wearable, non-invasive therapeutic that can produce results within a matter of days, compared to weeks or months with conventional therapies.”
In the spirit of the season, for each $5,000 investment NightWare will donate one device to someone who has not achieved coverage. For every $10,000, they will donate two devices; three devices for each $25,000 investment and five for each $50,000 investment.
For more information see the campaign page.
Disclaimer
No money or other consideration is being solicited, and if sent in response, will not be accepted. No offer to buy securities can be accepted, and no part of the purchase price can be received until the offering statement is filed and only through the intermediary's platform. An indication of interest involves no obligation or commitment of any kind.
About NightWare
NightWare is dedicated to eliminating Nightmare Disorder for patients and assisting the caretakers and clinicians who treat it. The company’s innovative platform has shown promise in providing relief to those suffering from this condition, and NightWare continues to work towards expanding its reach and impact. For more information about NightWare and its mission, please visit NightWare’s website.